Aminolevulinic Acid
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Aminolevulinic Acid: From Actinic Keratosis to Pre-malignant Neoplasm
One-Sentence Summary
Aminolevulinic acid (ALA) is a photosensitizer precursor, originally used for actinic keratosis and related skin conditions. The TxGNN model predicts it may be effective for pre-malignant neoplasm, with no registered clinical trials but 13 publications (including a systematic review and a 10-year randomized follow-up) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Actinic keratosis and related skin disease (knowledge-graph indications; the Singapore licence text lists no approved indication) |
| Predicted New Indication | Pre-malignant neoplasm |
| TxGNN Prediction Score | 96.01% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Based on known information, ALA is metabolized to protoporphyrin IX (PpIX), which accumulates preferentially in dysplastic and neoplastic cells. When activated by light, PpIX generates reactive oxygen species that selectively destroy these cells.
Actinic keratosis is itself a pre-malignant skin lesion. The new prediction, pre-malignant neoplasm, is therefore largely an extension of the same mechanism to other tissue sites. The literature covers pre-malignant lesions of the skin, oral mucosa, vulva and Barrett's oesophagus.
The evidence is heterogeneous across sites. Much of it consists of case reports, preclinical studies and diagnostic fluorescence studies rather than controlled trials.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40614840 | 2025 | RCT (10-year follow-up) | Photodiagn Photodyn Ther | Compared ALA-PDT, methyl aminolevulinate-PDT and surgery for nodular basal cell carcinoma |
| 25315968 | 2015 | Systematic review | Photodiagn Photodyn Ther | Efficacy of PDT in oral premalignant lesions |
| 26516853 | 2015 | Review | Int J Mol Sci | Combined PDT treatments for non-melanoma skin cancer |
| 18031503 | 2008 | Clinical study | J Eur Acad Dermatol Venereol | Fractionated ALA-PDT supports PDT use for non-melanoma skin cancer |
| 22594985 | 2012 | Comparative study | Photodiagn Photodyn Ther | ALA-PDT (48 patients) versus cryotherapy (37 patients) for oral leukoplakia |
| 12787039 | 2003 | Clinical study | J Oral Pathol Med | Topical ALA-PDT for oral leukoplakia |
| 31364444 | 2019 | Case report and review | J Int Med Res | PDT for vulvar intraepithelial neoplasia |
| 21035351 | 2011 | Animal study | J Photochem Photobiol B | Hypericin-PDT compared with methyl-ALA in a mouse actinic keratosis model |
| 19226578 | 2009 | Diagnostic study | Lasers Surg Med | Fluorescence detection of early non-melanoma skin cancer, including actinic keratosis |
| 19106058 | 2009 | Diagnostic study | Eur J Dermatol | ALA-induced fluorescence in 98 patients with skin and mucosal lesions |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15244P | GLIOLAN, powder for oral solution, 30 mg/ml (LyoContract GmbH) | Powder, for solution | Not stated in the compiled data |
Safety Considerations
- Knowledge-graph contraindication signals: photosensitivity disease and photoparoxysmal response. These come from a knowledge graph, not from label text.
- Drug Interactions: 94 interactions were identified. The major-level interactions listed in the compiled data include:
- Tetracyclines: doxycycline, tetracycline, minocycline (including topical)
- Sulfonylureas: chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, tolbutamide
- Levofloxacin and sulfasalazine
- Promethazine
- NSAIDs: ibuprofen, flurbiprofen
- Retinoids: isotretinoin, acitretin, adapalene (topical), alitretinoin (topical), tretinoin (topical)
Many of these are likely photosensitizing agents, so additive phototoxicity is a plausible concern.
Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism is the same as in the approved actinic keratosis use, and the literature includes a systematic review and a long-term randomized follow-up. There are no registered trials, and the evidence varies widely across tissue sites. The only Singapore licence (Gliolan, an oral-solution product) is not a topical PDT product, so route and product compatibility is unresolved.
To proceed, the following is needed:
- The package insert warnings and contraindications (HSA label), which are currently missing and block safety screening
- Detailed mechanism of action data (MOA)
- Definition of the specific pre-malignant lesion types and sites to target
- Confirmation of a suitable formulation and route for the target site, since the licensed product is not topical
- A photosensitivity management plan, including a review of interacting photosensitizing drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.